Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sanofi-Aventis Sees India As Major Site For Diabetes Treatments

This article was originally published in PharmAsia News

Executive Summary

France's Sanofi-Aventis sees India as a possible base for the company's global effort to be a major player in diabetes treatments. In addition to beginning research into India-specific drug combinations and marketing of its Apidra (glulisine recombinant) insulin in India later this year, the firm also may make the country a global hub for its insulin manufacturing. The French drug maker already has a 7.9 percent market share for oral diabetes drugs and insulin through its Indian arm, Aventis Pharma. The subsidiary relies on a large Indian market for combination drugs, spurring the move to India-specific treatments. (Click here for more

You may also be interested in...



Indian CROs Move Up R&D Value Chain From Outsourcing Services To Partnering With MNCs

NEW DELHI - India, along with China, is increasingly becoming a popular destination for pharmaceutical research and development outsourced from the West, and more multinational companies are partnering with Indian CROs to improve productivity, cut costs and bring more drugs to market faster

QUOTED. 5 August 2020. Eric Fanning.

AdvaMed’s VentConnect platform is expanding to support production of devices needed to treat COVID-19. Here’s what Eric Fanning, CEO of participating group the Aerospace Industries Association, said about the move.

Warp Speed Lives Up To Its Name: FDA Planning Late October Vaccine Advisory Committee

Preliminary plans for an Oct. 22 meeting of US FDA's vaccine advisory committee suggest a fast evaluation of COVID-19 immunizations, bringing mixed reactions from onlookers who say it could be a positive sign of needed public transparency or an indication the agency is rushing to approve a product ahead of the November presidential election.

UsernamePublicRestriction

Register

SC027449

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel